Organon & Co
$ 13.60
0.37%
07 Aug - close price
- Market Cap 3,558,358,000 USD
- Current Price $ 13.60
- High / Low $ 13.61 / 13.55
- Stock P/E 17.37
- Book Value 3.83
- EPS 0.78
- Next Earning Report -
- Dividend Per Share $0.08
- Dividend Yield 0.59 %
- Next Dividend Date 2026-09-10
- ROA 0.06 %
- ROE 0.24 %
- 52 Week High 13.61
- 52 Week Low 5.68
About
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Analyst Target Price
$11.25
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-31 | 2026-04-30 | 2026-02-12 | 2025-11-10 | 2025-08-05 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-15 | 2023-11-02 |
| Reported EPS | 0.8 | 0.71 | 0.63 | 1.01 | 1 | 1.02 | 0.9 | 0.87 | 1.12 | 1.22 | 0.88 | 0.87 |
| Estimated EPS | 0.85 | 0.85 | 0.73 | 0.93 | 0.94 | 0.89 | 0.87 | 0.9 | 1.08 | 0.93 | 0.83 | 1.06 |
| Surprise | -0.05 | -0.14 | -0.1 | 0.08 | 0.06 | 0.13 | 0.03 | -0.03 | 0.04 | 0.29 | 0.05 | -0.19 |
| Surprise Percentage | -5.8824% | -16.4706% | -13.6986% | 8.6022% | 6.383% | 14.6067% | 3.4483% | -3.3333% | 3.7037% | 31.1828% | 6.0241% | -17.9245% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-09-10 | 2026-06-11 | 2026-03-12 | 2025-12-11 | 2025-09-11 | 2025-06-12 | 2025-03-13 | 2024-12-12 | 2024-09-12 | 2024-06-13 |
| Amount | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0.28 | $0.28 | $0.28 | $0.28 |
Next Dividend Records
| Dividend per share (year): | $0.08 |
| Dividend Yield | 0.59% |
| Next Dividend Date | 2026-09-10 |
| Ex-Dividend Date | 2026-08-14 |
Recent News: OGN
2026-08-01 02:41:26
Vanguard Portfolio Management LLC and affiliated entities have reported a beneficial ownership of 15,161,710 shares in Organon & Co, constituting a 5.77% stake in the company. Vanguard holds sole voting power over 29,592 shares and sole dispositive power over all 15.16 million shares. This disclosure, filed as an amended SCHEDULE 13G/A, aggregates holdings from various Vanguard funds and managed accounts.
2026-07-31 15:39:13
Organon (NYSE: OGN) has announced a quarterly dividend of $0.28 per share of common stock. The dividend is payable on September 12, 2024, to shareholders of record as of the close of business on August 21, 2024.
2026-07-31 13:41:26
Organon & Co. (NYSE: OGN) has announced a quarterly dividend of $0.02 per share of common stock. This dividend is scheduled to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. Organon is a healthcare company based in Jersey City, New Jersey, focusing on women’s health and general medicines across over 140 markets.
2026-07-31 12:40:30
Organon & Co. reported its 2026 quarterly results, showing a decline in revenue, net income, and diluted EPS compared to the prior-year quarter. Revenue was $1.56 billion, with a diluted EPS of $0.4. The company is in the process of being acquired by Sun Pharma and is undergoing restructuring.
2026-07-30 10:10:27
Organon & Co (OGN) stock currently trades at $13.545, with its fundamentals described as stable and growth potential high. TradingKey rates its valuation as "fairly valued" within the Pharmaceuticals industry, although it notes the stock is considered overvalued based on its PE ratio. Institutional ownership is very high, but there has been a slight decrease in holdings quarter-over-quarter.
2026-07-27 20:43:10
This article provides a detailed company profile of Organon & Co (OGN), a global healthcare company specializing in women's health, biosimilars, and established medicines. It includes financial data, market performance, executive compensation, and shareholding information. The company's main revenue source is its Women's Health business.
